CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

a study on Fibrosis Idiopathic Pulmonary Fibrosis

Summary

Eligibility
for people ages 40 years and up (full criteria)
Location
at Orange, California and other locations
Dates
study started
estimated completion

Description

Summary

This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of CSL312 in subjects with idiopathic pulmonary fibrosis (IPF).

Official Title

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis

Keywords

Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Fibrosis, CSL312

Eligibility

You can join if…

Open to people ages 40 years and up

  • Male or female patients ≥ 40 years of age
  • Documented diagnosis of IPF

You CAN'T join if...

  • History of clinically significant cardiovascular disease, including myocardial infarction, unstable ischemic heart disease, congestive heart failure, or angina during the 6 months before screening
  • Sinoatrial or atrioventricular block, uncontrolled hypertension
  • Active bleeding or current clinically significant coagulopathy

Locations

  • University of California Irvine accepting new patients
    Orange California 92868 United States
  • National Institute of Clinical Research accepting new patients
    Huntington Beach California 92647 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
CSL Behring
ID
NCT05130970
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 80 study participants
Last Updated
Contact us about this trial